Unexpected acute pulmonary embolism in an old COVID-19 patient with warfarin overdose: a case report

Maxime Coutrot¹,2,3*, Maxime Delrue⁴,⁵, Bérangère S. Joly⁴,⁵, and Virginie Siguret⁴,⁶

¹Department of Anaesthesiology, Critical Care Medicine and Burn Unit, AP-HP, Saint Louis and Lariboisière University Hospitals, 1 Avenue Claude Vellefaux, 75010 Paris, France; ²INSERM UMR-S 942, 41 boulevard de la Chapelle, 75475 Paris Cedex 10, Lariboisière Hospital, Paris, France; ³THU PROMICE, 2 Rue Ambroise Pare, 75010 Paris, France; ⁴Service d'hématologie biologique, Hôpital Lariboisière, 2 rue Ambroise Pare, 75010 Paris, Université de Paris, Paris, France; ⁵ÉA 3518, Institut de Recherche Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, Université de Paris, Paris, France; and ⁶INSERM UMR-S 1140 Innovations thérapeutiques en Hémostase, Faculté de Pharmacie, 4 avenue de l'Observatoire, 75270 Paris CEDEX 06, Université de Paris, Paris, France

Received 4 January 2021; first decision 2 February 2021; accepted 12 May 2021

Background
Severe acute respiratory syndrome coronavirus 2 disease is strongly associated with a high incidence of thrombotic events. Anticoagulation could be a cornerstone in successfully managing severe forms of coronavirus disease 2019 (COVID-19). However, optimal anticoagulant dosing in elderly patients is challenging because of high risk of both thrombosis and bleeding.

Case summary
We present here the case of an 89-year-old patient receiving warfarin for atrial fibrillation and valvular heart disease, admitted to the intensive care unit for respiratory failure due to COVID-19. The patient presented with a severe epistaxis associated with warfarin overdose [international normalized ratio (INR) > 10]. After a successful initial reversal using vitamin K₁ per os, INR values greatly fluctuated up to 10, requiring repeated administrations of vitamin K. Despite starting low-molecular-weight heparin therapy at therapeutic dose as soon as INR value was below 2.0, the patient further developed an acute bilateral and proximal pulmonary embolism concomitantly with a sharp D-dimer increase. The combination of azithromycin intake, a known inhibitor of CYP2C9, with the presence of CYP2C9*2 and CYP2C9*1639G>A VKORC1, two variants associated with warfarin hypersensitivity, have likely contributed to explain the warfarin overdose and the difficulty to reverse warfarin effect in this patient.

Discussion
This case report illustrates the complexity of COVID-19 pathophysiology and its management for physicians, especially in patients receiving vitamin K antagonists (VKAs). Infection, concurrent medication use, and pharmacogenetic factors involved in VKA metabolism and pharmacodynamics may lead to a loss of control of anticoagulation. Pulmonary embolism should still be considered in COVID-19 patients even with effective or overdosed anticoagulant therapy.

Keywords
COVID-19 • Warfarin • Overdose • Pulmonary embolism • D-dimer • Case report

* Corresponding author. Tel: +33142499394, Email: maxcoutrot@yahoo.fr
Handling Editor: Rita Pavasini
Peer-reviewers: Sabato Sorrentino and Faten Yahia
Compliance Editor: Ayse Djahit
Supplementary Material Editor: Edwina McNaughton
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has largely been associated with a high incidence of arterial or venous thrombotic events, especially in the most severe patients.\(^1\) Indeed, the pathophysiology of this novel coronavirus disease (COVID-19) includes mild and dysregulated inflammation,\(^2,3\) vascular dysfunction, and coagulopathy.\(^2,4,5\) Together with steroids, anticoagulation therapy is one of the cornerstones in the treatment of severe forms of COVID-19.\(^6\) Moreover, COVID-19 patients on oral anticoagulant treatment for atrial fibrillation seem to be at lower risk of all-cause mortality compared to non-anticoagulated counterparts.\(^7\) However, the choice of the anticoagulant drug is still debated, especially in the most severe patients.\(^8,9\)

To illustrate the unusual coagulation disorders in COVID-19, we describe and discuss here the case of an elderly patient with warfarin overdose and major bleeding upon admission, further managed in intensive care unit (ICU) for a severe acute respiratory failure due to COVID-19 and developing a pulmonary embolism.

Timeline

| Timeline | Event |
|---------|-------|
| During the 6 months prior to admission | International normalized ratio (INR) was over 2 taking warfarin for atrial fibrillation and valvular heart disease |
| Ten days before admission (Day 0) | Patient was tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), treated with spiramycin and then azithromycin |
| Clinical presentation at emergency department admission (Day 10) | Major bleeding: epistaxis |
| Biology at admission (Day 10) | Well tolerated hypoxaemia related to SARS-CoV-2 infection: |
| | • Pulse oxygen saturation: 80% in air |
| | • Systolic blood pressure: 105 mmHg; Diastolic blood pressure: 59 mmHg; Cardiac rate: 104 per minute |
| Computed tomography (CT) scan at admission (Day 10) | INR > 10 |
| | D-dimers: 400 ng/mL (<500 ng/mL) |
| | B-type natriuretic peptide: 81 pg/mL (<100 pg/mL) |
| | High-sensitivity troponin T: 10 ng/L (<34 ng/L) |
| Intensive care unit stay (Days 10–26) Days 13, 15, and 17 | Non-enhanced CT scan: ground-glass opacity, crazy paving, and air space consolidation of ~50% of both lungs, related to coronavirus disease 2019 |
| Day 17 | Three further administrations of vitamin K were necessary to achieve a stable INR value between 2 and 3 |
| | D-dimer > 12 000 ng/mL (<500 ng/mL) |
| | Enhanced CT scan: acute proximal bilateral pulmonary embolism |
| Day 26 | Patient was discharged on low-molecular-weight heparin and on 2 L/min of oxygen |

Learning points

- Numerous acquired and pharmacogenetic factors are likely to contribute to over-anticoagulation in patients in acute conditions receiving warfarin, especially in elderly coronavirus disease 2019 (COVID-19) patients.
- Clinicians should still consider acute pulmonary embolism in COVID-19 patients even with effective or overdosed anticoagulant therapy, especially if D-dimer level sharply increases.

Case presentation

An 89-year-old Caucasian man, body weight 82 kg, presented fever and cough for a week (Days 0–7). His usual drug treatment included warfarin, bisoprolol, ramipril, and furosemide for valvular heart disease (mitral bioprosthesis and tricuspid valvuloplasty) with atrial fibrillation and hypertension. During the 6 months prior to the COVID-19, international normalized ratio (INR) values performed monthly were all above 2. The COVID-19 diagnosis was positive (Day 0), confirmed by the reverse transcriptase-polymerase chain reaction SARS-CoV-2. He was initially managed as an outpatient by his general practitioner and was prescribed amoxicillin (Days 0–2), spiramycin (Days 2–4), and finally azithromycin (Days 4–12) (Figure 1). No INR control was performed over this period.

On Day 10, the patient was admitted to the emergency department (ED) with epistaxis, classified as major bleeding (drop in haemoglobin level >2 g/dL, Hb 7.3 on Day 13). Systolic blood pressure was 105 over 59 mmHg and heart rate was of 104 beats per minute. Breathing rate was of 22 per minute, and lung auscultation revealed rare medium-coarse crackles. Heart sounds were irregular, without cardiac murmur, and no clinical signs of congestion were noted. The INR value was above 10. The patient received 10 mg of vitamin K per
os and simple compression therapy stopped the bleeding. Liver injury was ruled out by slightly increased factor V levels [166 IU/dL (70–130 IU/dL)] and serum levels of alanine and aspartate aminotransferases in normal ranges [38 IU (<41 IU/L) and 36 IU/L (<40 IU/L), respectively]. Fibrinogen level was 7.6 g/L (2.0–4.0 g/L) and plasma D-dimer level was only of 400 ng/mL (<500 ng/mL) in this patient on warfarin.

The patient was deeply hypoxemic at the ED, with a pulse oxygen saturation of 80%, and the respiration rate was measured at 20 per minute. Oxygen therapy using facial mask with 9 L/min was required to achieve normoxia. The non-enhanced computed tomography scan (CT scan) performed revealed severe lung damage, interesting 50% of both lungs, consisting of ground-glass opacity, crazy paving, and air space consolidation. The CT scan also showed an important dilatation of the colon, in this patient suffering from chronic transit disorders. Both CT scan and laboratory data were inconsistent with cardiogenic pulmonary oedema [B-type natriuretic peptide (BNP): 81 pg/mL (<100 pg/mL)], but rather consistent with severe SARS-CoV-2 related pneumonia.

The patient was then transferred to the ICU. The treatment consisted of dexamethasone 6 mg per day for 10 days, cefotaxime and azithromycin (stopped on Day 12 after bacterial infection was ruled out), the patient’s regular medications, and standard oxygen therapy. The patient received repeated 5 mg intravenous administrations of vitamin K because of great INR fluctuations from 2.0 to 10.0 (Figure 1). As soon as INR value was below 2.0, subcutaneous enoxaparin (100 IU/kg) twice daily was introduced on Day 16. On Day 17, after a slight improvement, the patient became more hypoxemic and D-dimer increased dramatically over 12,000 ng/mL. Another computed tomography with pulmonary angiography (CTPA) showed the persistence of the lesions previously observed, but also an acute proximal bilateral pulmonary embolism (Figure 2). NT-proBNP and highsensitivity troponin T levels were slightly increased at 2022 ng/L (<600 ng/L) and 48.9 ng/L (<34 ng/L), respectively, in this context of severe COVID-19, and the patient did not present any haemodynamic instability or acute right ventricular failure on echocardiography or CT scan. In this context of recent severe bleeding, thrombolytic therapy was therefore not performed, and the treatment consisted in continuing the already started anticoagulation with enoxaparin at the same dose, switched to tinzaparin (175 IU/kg) once daily on Day 21 until ICU discharge (Figure 1).

Antithrombin activity, protein C chromogenic activity, and free protein S antigen measured on Day 18 were in the normal range; G20210A F2 or G1691A F5 variants were absent. Screening for antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, and antiβ2-glycoprotein I) was negative.

In order to better understand unusual prolonged over-anticoagulation in spite of warfarin withdrawn and repeated administration of
vitamin K, we sought to genotype the patient for genetic variants contributing to explain hypersensitivity to warfarin: cytochrome P450 2C9 (CYP2C9*2 and *3) involved in warfarin metabolism and -1639G>A vitamin K epoxide reductase complex subunit I (VKORC1) variant, the pharmacological target of vitamin K antagonist (VKA), after the patient gave his consent. He was found heterozygote for CYP2C9*2 which confers to the patient a slow metabolizer phenotype and -1639G>A VKORC1.

Finally, the patient improved slowly, he was discharged from ICU on Day 26 with nasal oxygen therapy at 2 L/min. Two days after the admission to the medical ward, the patient’s clinical condition worsened again because of a non-documented bacterial pneumonia based on fever, increased biological inflammatory syndrome, and new radiological infiltrates. Pneumologists and intensivists decided not to readmit the patient to the ICU. Despite the initiation of broad-spectrum antibiotic therapy, the patient died from septic shock a week later. Cardiac biomarkers, echocardiography, or CT scan were not performed. Low-molecular-weight heparin (LMWH) therapy was continued at therapeutic dose, and D-dimer levels did not increase.

**Discussion**

Infection and concurrent medication use expose VKA-treated COVID-19 patients to the risk of high INR fluctuations. Our case highlights the severe haemostasis disorders associated with SARS-CoV-2 infection and raises some concerns about the close monitoring of INR in COVID-19 patients.

The anticoagulant effect of warfarin is influenced by several acquired and pharmacogenetic factors. Antibiotics and digestive disorders may dramatically alter the intestinal flora and decrease the endogenous vitamin K production, thus decreasing the warfarin dose requirement.

Additionally, drug interactions with warfarin may frequently lead to over-anticoagulation. Indeed, warfarin is metabolized by CYP2C9, CYP1A2, and CYP3A4. Many inhibitors of these CYP are identified as...
potentiating warfarin’s effect. Moreover, CYP2C9*2 and VKORC1 -1639G>A variants contribute to inter-individual variability in the response to warfarin: they are associated with a significant decrease in warfarin requirement and an increased risk of adverse haemorrhagic events. It is likely that the effects of CYP2C9 variant were amplified by concurrent medication use, especially azithromycin, a known inhibitor of CYP2C9, thus prolonging warfarin half-life in our patient, and making unstable warfarin reversal. Recently, other groups also reported over-anticoagulation in COVID-19 patients on VKA therapy (i.e. use of antibiotics).

Vitamin K 10 mg per os was given to our patient according to recommendations. Iterative vitamin K supplementation was further needed due to the INR fluctuations up to 10 during ICU stay. The occurrence of acute pulmonary embolism notwithstanding anticoagulant therapy at therapeutic dose is unusual. Indeed, the time spent below 2.0 was short (only a few hours): an imbalance between the vitamin K-dependent protein C anticoagulant activity with a short half-life (4–6 h) and the vitamin K-dependent factor procoagulant activities with half-lives ranging from 6 to 60 h may have contributed to exacerbate the hypercoagulability state. Moreover, stasis combined with endothelial dysfunction leading to high levels of von Willebrand factor and FVIII contribute to explain high thrombotic events rates in COVID-19 patients.

After VKA reversal, LMWH was prescribed at usual therapeutic dosage and was not increased after pulmonary embolism diagnosis because of the recent major bleeding and the lack of data supporting increased anticoagulant regimens use in COVID-19 patients receiving long-term anticoagulant therapy. On this last point, clinical trials are ongoing (ACTIV-4).

Fibrinogen should be interpreted along with D-dimer levels for better prognostic information: its gradual decrease together with a sharp increase in D-dimer levels may raise the suspicion of an acute thrombotic event, and therefore may lead to the assessment of CTPA examination and/or the intensification of anticoagulation therapy. A sharp increase in D-dimer levels may raise the suspicion of an acute ongoing (ACTIV-4).

Conclusion

First, this case illustrates the combination of acute conditions (infection and concurrent medication use) with warfarin CYP2C9*2 and -1639G>A VKORC1 variants leading to a major bleeding event and requiring repeated vitamin K administrations. Clinicians should be aware of these factors leading to potential over-anticoagulation in patients on VKA therapy, making a switch for LMWH is recommended for severe COVID-19 patients. Second, the occurrence of pulmonary embolism in a COVID-19 patient receiving anticoagulant therapy highlights the complex mechanisms supporting haemostasis disorders in COVID-19. In case of acute respiratory failure in COVID-19 patients, particularly when D-dimer levels increased significantly, pulmonary embolism should be ruled out including patients treated with VKA.

Lead author biography

Maxime Coutrot: after completing his Master’s degree in Cardiovascular Sciences, he is working on reno-cardiac syndrome conducted in Inserm research unit UMR-S 942. Maxime Coutrot received his Medical degree from the Faculty of Medicine of Paris Sud, and holds a diploma in Anesthesiology and Intensive Care. He is currently a hospital practitioner in the Department of Anesthesiology, Intensive Care Unit and Burn Unit at Saint-Louis University Hospital in Paris.

Supplementary material

Supplementary material is available at European Heart Journal - Case Reports online.

Acknowledgements

The authors thank Prof. Alexandre Mebazaa and Dr François Depret for their proofreading as well as their advices for the writing of this case, and Dr Damien Bouda for providing the CT scan images.

Slide sets: A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient in line with COPE guidance.

Conflict of interest: None declared.

Funding: None declared.

References

1. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Septis Trial Group for Global Evaluation and Research in Septis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089–1098.
2. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71:762–768.
3. Joly BS, Siguret V, Veyradier A. Understanding pathophysiology of haemostasis disorders in critically ill patients with COVID-19. Intensive Care Med 2020;46:1603–1606.
4. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 2020;7:e438–e440.
5. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welter T, Laenger F et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020;383:120–1288.
6. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75:2950–2973.
7. Denas G, Gennaro N, Ferroni E, Fedeli U, Lorenzoni G, Gregori D et al. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: a population-based propensity score matched study. Int J Cardiol 2021;329:266–269.
8. Hasan SS, Radford S, Kow CS, Zaidi STR. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis 2020;50:814–821.
9. Jonmarker S, Hollenberg J, Dahlberg M, Stackelberg O, Litorell J, Everhov ÅH et al. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit Care 2020;24:653.

10. Holbrook AM. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095–1106.

11. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690–1698.

12. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ et al. Evidence-based management of anticoagulant therapy. Chest 2012;141:e1525–e1845.

13. Trevisan C, Miconi L, Barbierato E, Marinaro G, Targhetta S, D’agata M et al. Labile PT-INR in a Covid-19 patient under long-term vitamin K antagonist therapy: a case report. SN Compr Clin Med 2020;2:1680–1682.

14. Voicu S, Bonnin P, Stépanian A, Chousterman BG, Le Gall A, Malissin I et al. High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients. J Am Coll Cardiol 2020;76:480–482.